Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Protalix BioTherapeutics, Inc.PLX · Entity 2671 | Director | September 07, 2022 | September 09, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Protalix BioTherapeutics, Inc.
Report date September 07, 2022 · Filed September 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.03 · Expires 2032-09-07 | Direct | 100,000 |
Reported balance
After 2022-09-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-09-07 · Grant · Acquired 100,000 · Balance 100,000 F1: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended, or if the Reporting Person ends his tenure on the Board of Directors within 12 months of the date of grant. F2: Does not include options to purchase 240,000 shares of common stock at an exercise price equal to $3.70 per share that expire on February 3, 2030. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended, or if the Reporting Person ends his tenure on the Board of Directors within 12 months of the date of grant.
F2: Does not include options to purchase 240,000 shares of common stock at an exercise price equal to $3.70 per share that expire on February 3, 2030.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 07, 2022 Filed Sep 9, 2022 21:01 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantStock Options (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001104659-22-098947 · tm2225460-4_4seq1.xml · derivative · entry 1 Bronfeld Zeev · CIK 0001298522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-09-07 F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended, or if the Reporting Person ends his tenure on the Board of Directors within 12 months of the date of grant. F2 · balance_after: Does not include options to purchase 240,000 shares of common stock at an exercise price equal to $3.70 per share that expire on February 3, 2030. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:01 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantStock Options (Right to Buy) · Derivative | 240,000 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001104659-20-011315 · tm205452-3_4.xml · derivative · entry 1 Bronfeld Zeev · CIK 0001298522 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2030-02-03 F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.